Multi-center, randomized, double-blind, placebo-controlled study of two dosages of AM3301 for add-on treatment of mild to moderate active ulcerative colitis.

Trial Profile

Multi-center, randomized, double-blind, placebo-controlled study of two dosages of AM3301 for add-on treatment of mild to moderate active ulcerative colitis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs AM 3301 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Kemin Pharma
  • Most Recent Events

    • 01 Jul 2010 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India record.
    • 21 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top